XML 33 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Cash, Cash Equivalents, and Short-Term marketable securities
 12 Months Ended
Dec. 31, 2022
Cash and Cash Equivalents [Abstract]  
Cash, Cash Equivalents, and Short-Term marketable securities Cash, Cash Equivalents, and Short-Term marketable securities
Cash and cash equivalents
The following table summarizes the Company's cash, cash equivalents, and restricted cash as of December 31, 2022 and 2021.
(in thousands)Year Ended
December 31, 2022		Year ended December 31, 2021
Beginning
of period		End
of period		Beginning
of period		End
of period
Cash and cash equivalents$177,947 $128,885 $255,094 $177,947 
Restricted cash included in other assets, noncurrent478 478 321 478 
Total cash, cash equivalents and restricted cash per statement of cash flows$178,425 $129,363 $255,415 $178,425 
Marketable securities
The following table summarizes the Company's marketable securities held at December 31, 2022. The Company had no marketable securities as of December 31, 2021.

December 31, 2022
(in thousands)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
Marketable securities
U.S. treasury securities$107,964 $7 $(161)$107,810 
U.S. government agency securities44,016 24 (23)44,017 
$151,980 $31 $(184)$151,827 

All of the Company's marketable securities are due within one year or less. The Company did not realize any gains or losses recognized on the sale of marketable securities during the year ended December 31, 2022, and, as a result, the Company did not reclassify any amounts out of accumulated comprehensive loss.
As of December 31, 2022, the Company's debt security portfolio consisted of 17 securities that were in an unrealized loss position and had an aggregate fair value of $92.8 million. There were no securities in an unrealized loss position for greater than 12 months as of December 31, 2022. The unrealized losses on the Company's marketable securities were caused by market interest rate increases. The Company has the intent and ability to hold such securities until recovery. As a result, the Company did not record any charges for credit-related impairments for its marketable securities during the year ended December 31, 2022.